Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide

Bibliography

• TOWNSEND R, HAGGERT B, LISS C et al: Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Clin. Titer: (1995) 17:911–923.
   Google Scholar
• LAROCHELLE P, FLACK JM, MARBURY TC et al: Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators. Am.j Cardiol. (1997) 80:1613–1615.
   Web of Science ®Google Scholar
• RAGOT S, EZZAHER A, MEUNIER A et al.: Comparison of trough effect of telmisartan versus perindopril using self blood pressure measurements:EVEREST Study. .1. Hum. Hypertens.(2002) 16:865–873.
   Google Scholar
• ZANCHETTI A, OMBONI S, BIAGI C: Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension.' Hum. Hypertens. (1997) 11\(Suppl. 2):557–559.
   Google Scholar
• GAVRAS I, GAVRAS H: Efficacy of eprosartan versus enalapril in hypertensive patients on the renin angiotensin-aldosterone system and safety parameter: results from the 26-week, double blind, multicenter study. Eprosartan Multinational Study Group. Carr. Med. Res. Opin. (1999) 15:15–24.
   PubMed Web of Science ®Google Scholar
• LACOURCIERE Y, BRUNNER H, IRWIN R et al: The Losartan Cough Study Group. Effects of modulators of the renin-angiotensin-aldosterone system on cough.Hypertens. (1994) 12:1387–1393.
   Google Scholar
• LACOURCIERE Y: The incidence of cough: a comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist. Telmisartan Study Group. Int.j Clin. Pratt (1999) 53:99–103.
   PubMedGoogle Scholar
• VIDT DG: Can angiotensin II receptor blockers be used in patients who have developed a cough or angioedema as a result of taking an ACE inhibitor?Cleve. Clin. J. Med. (2001) 68:189–190.
   Google Scholar
• GRANGER CB, MCMURRAY JJ, YUSUF S et al: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-Alternative Trial. Lancet (2003) 362:772–776.
   PubMed Web of Science ®Google Scholar
• ••Latest outcomes study of the CHARM group showing reduction of cardiovascular events by candesartan compared to placebo in patients with heart failure intolerant to ACE inhibitors.
   Google Scholar
• PFEFFER MA, SWEDBERG K, GRANGER CB et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Progamme. Lancet (2003) 362:759–766.
   PubMed Web of Science ®Google Scholar
• ••Large database of the CHARM studies inpatients with heart failure and systolic or LV diastolic dysfunction.
   Google Scholar
• MCMURRAY JJ, OSTERGREN J, SWEDBERG K et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-Added Trial. Lancet (2003) 362:767–771.
   PubMed Web of Science ®Google Scholar
• ••Latest outcomes study of the CHARMgroup showing greater reduction in cardiovascular events by candesartan added to ACE inhibitors versus ACE inhibitors alone in patients with heart failure.
   Google Scholar
• COHN JN, TOGNONI G: Valsaitan Heart Failure Trial Investigators. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N. Engl.' Med. (2001) 345:1667–1675.
   Google Scholar
• ••Large outcomes study showing reductionin cardiovascular events by valsartan versusplacebo in patients with heart failure.
   Google Scholar
• WONG M, STASZEWSKY L, LATINI R et al: Valsartan benefits left ventricular structure and function in heart failure. Val-HeFT echo-cardiographic study.Am. Coll. Cardiol. (2002) 40:970–975.
   PubMed Web of Science ®Google Scholar
• •Interesting sub-study of Val-HeFT study.
   Google Scholar
• DAHLOF B, DEVEREUX RB, KJELDSEN SE et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomized trial against atenolol. Lancet (2002) 359:995–1003.
   PubMed Web of Science ®Google Scholar
• ••Large outcomes study, showing superiorityof losartan to atenolol in reversing LVH in high-risk, hypertensive patients.
   Google Scholar
• LEWIS EJ, HUNSICKER LG,CLARKE WR et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N Engl. I Med.(2001) 345:851–860.
   PubMed Web of Science ®Google Scholar
• ••Large outcomes study showing therenoprotective effects of irbesartan compared to amlodipine and placebo, in hypertensive patients with diabetic nephropathy.
   Google Scholar
• BRENNER BM, COOPER ME, DEZEEUW D et al.: Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl. I Med. (2001) 345:861–869.
   PubMed Web of Science ®Google Scholar
• ••Large outcomes study showing therenoprotective effects of losartan compared to placebo in hypertensive patients with diabetic nephropathy.
   Google Scholar
• ICHIKAWA S, TAKAYAMA Y: Long-term effects of olmesartan, an Ang II receptor antagonist, blood pressure and the renin angiotensin-aldosterone system in hypertensive patients. Hypertens. Res. (2001) 24:641–646.
   PubMed Web of Science ®Google Scholar
• POCHLER K, LAEIS P, STUMPE KO: Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. Hypertens. (2001) 19\(Supp1.1):541–548.
   Google Scholar
• ••Large database analysis of hypertensivepatients treated with different doses of olmesartan medoxomil.
   Google Scholar
• NEUTE1JM, ELLIOTT WJ, IZZO JL et al.: Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements.Clin. Hypertens. (2002) 4:325–331.
   Google Scholar
• WARNER GT, JARVIS B: Olmesartan medoxomil. Drugs (2002) 62:1345–1353.
   PubMed Web of Science ®Google Scholar
• ••Concise review of olmesartan medoxomil.
   Google Scholar
• GARDNER SF, FRANKS AM: Olmesartanmedoxomil: the seventh angiotensin receptor antagonist. Ann. Pharmacother. (2003) 37:99–105.
   PubMed Web of Science ®Google Scholar
• KOIKE H, SADA T, MIZUNO M: In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type ATI receptor antagonist.AHypertens. (2001) 19\(Supp1.1):S3–S14.
   Google Scholar
• SCHWOCHO LR, MASONSON HN: Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. Clin. Pharmacol. (2001) 41:515–527.
   Google Scholar
• VONBERGMAN K, LAEIS P, POCHLER K et al.: Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil.j Hypertens. (2001) 19\(Supp1.1):S33–S40.
   Google Scholar
• ••A large study comparing the effects of age, renal and liver function of hypertensive patients treated with olmesartan medoxomil.
   Google Scholar
• LAEIS P, PUCHLER K, KIRCH W: The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. Hypertens. (2001) 19\(Supp1.1):S21–S32.
   Google Scholar
• MIZUNO M, SADA T, IKEDA M et al.: Pharmacology of CS-866, a novel non-peptide angiotensin II receptor antagonist. Eur. Pharmacol (1995) 285:181–188.
   PubMed Web of Science ®Google Scholar
• KOIKE H: New pharmacologic aspects of CS-866, the newest angiotensin II receptor antagonist. Am. J. Cardiol (2001) 87:33–36.
   PubMed Web of Science ®Google Scholar
• MIYAZAKI M, TAKAI S: Anti-atherosclerotic efficacy of olmesartan. J. Hum. Hypertens. (2002) 16 (Suppl. 2):S7–S12.
   Google Scholar
• BRUNNER HR, NUSSBERGER J: Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an ATI receptor antagonist. Hypertens. (2001) 19\(Suppl. 1):S15–S20.
   Google Scholar
• ••Interesting model study in predicting theresponse to antihypertensive drugs.
   Google Scholar
• CHRYSANT SG: Vascular remodeling: the role of angiotensin converting enzyme inhibitors. Am. Heart J. (1998) 135:S21–S30.
   Google Scholar
• ••Interesting review of the role of A-II oncardiovascular remodeling and its reversal.
   Google Scholar
• CHRYSANT SG: Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan/HCTZ). Expert Rev Cardiovasc. Ther. (2003) 1:335–343.
   PubMedGoogle Scholar
• TAKAI S, TIN D, SAKGUCHI M, MIYAZAKI M: Chymase-dependent angiotensin II formation in human vascular tissue. Circulation (1999) 100:654–658.
   PubMedGoogle Scholar
• ••Evidence of A-II production byalternate pathways.
   Google Scholar
• IHARA M, URATA H, KINOSHITA A et al.: Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension (1999) 33:1399–1405.
   PubMed Web of Science ®Google Scholar
• ••Evidence of A-II production byalternate pathways.
   Google Scholar
• HOLLENBERG NK, FISHER ND, PRICE DA: Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension (1998) 32:387–392.
   Google Scholar
• ••Evidence of A-II production byalternate pathways.
   Google Scholar
• JUILLERA I, NUSSBERGER J, MENARD J et al.: Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension (1990) 16:564–572.
   PubMedGoogle Scholar
• SIRAGY HM: Angiotensin receptor blockers: How important is selectivity? Am. Hypertens. (2002) 15:1006–1014.
   Google Scholar
• UNGER T: Pharmacology of ATI receptor blockers. Blood Press. (2001) 10 (Suppl. 3):5–10.
   Google Scholar
• BALL KJ, WILLIAMS PA, STUMPE KO: Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. Hypertens. (2001) 19\(Supp1.1):S49–S56.
   Google Scholar
• ••A large database of studies comparing theeffects of olmesartan medoxomil with other drugs in the treatment of hypertension.
   Google Scholar
• STUMPE KO, LUDWIG M: Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J. Hum. Hypertens. (2002) 16\(Suppl. 2):S24–S28.
   Google Scholar
• CHRYSANT SG, MARBURY TC, ROBINSON TD: Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J. Hum. Hypertens. (2003) 17:425–432.
   PubMed Web of Science ®Google Scholar
• •Interesting study comparing the antihypertensive effects of olmesartan medoxomil versus amlodipine.
   Google Scholar
• OPARIL S, WILLIAMS D, CHRYSANT SG et al.: Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. Clin. Hypertens. (2001) 3:283–291.
   Google Scholar
• ••An interesting study comparing theantihypertensive effects of olmesartan medoxomil versus losartan, valsartan and irbesartan.
   Google Scholar
• CHRYSANT SG, WEBER MA, WANG AC et al.: Efficacy and safety of olmesartan medoxomil/hydrochlorothiazide combination therapy in hypertension. Am. J. Hypertens. (2004) (In Press).
   Google Scholar
• ••Interesting study comparing the antihypertensive effects of various doses of olmesartan medoxomil, alone and in combination with a diuretic.
   Google Scholar
• CHRYSANT SG, WOMBOLT DG, FELICIANO N et al.: Long-term efficacy, safety and tolerability of valsartan and hydrochlorothiazide in patients with essential hypertension. Carr: Ther. Res. (1998) 59:762–772.
   Web of Science ®Google Scholar
• LITTLEJOHN T 3rd, SAINI R, KASSLER-TAUB K et al: Long-term safety and antihypertensive efficacy of irbesartan. Pooled results of five open-label studies. Clin. Exp. Hypertens. (1999) 21:1273–1295.
   Google Scholar
• CHRYSANT SG, FOR THE LISINOPRIL-HYDROCHLORO-THIAZIDE GROUP: Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination: a large multicenter study. Arch. Intern. Med. (1994) 154:737–743.
   PubMed Web of Science ®Google Scholar
• CHRYSANT SG, FAGAN T, GLAZER R, FRIEDMAN A: Effects of benazepril and hydrochlorothiazide, given alone and in low and high dose combinations on blood pressure in patients with hypertension. Arch. Fam. Med. (1996) 5:17–14.
   PubMedGoogle Scholar
• CHRYSANT SG: Perindopril/hydrochlorothiazide dose combinations for the treatment of hypertension: a multicenter study. Clin. Pharmacol (1997) 37:47–52.
   Google Scholar
• CHRYSANT SG, CHRYSANT GS: Pharmacological profile and clinical use of moexipril. Expert Rev. Cardiovasc. Ther. (2003) 1:345–352.
   PubMedGoogle Scholar
• CHRYSANT SG: Fixed low-dose drug combination for the treatment of hypertension. Arch. Fam. Med. (1998) 7:370–376.
   PubMedGoogle Scholar
• DAHLOFF B: Left ventricular hypertrophy and angiotensin II antagonists. Am. J. Hypertens. (2001) 14:174–182.
   PubMedGoogle Scholar
• ••An interesting review on the role of ARBsin regressing LVH.
   Google Scholar
• KJELDSEN SE, JULIUS S, BRUNNER H et al.: Characteristics of 15,314 hypertensive patients at high risk. The VALUE trial: the Valsartan Antihypertensive Long-term Use Evaluation. Blood Press. (2001) 10:83–91.
   Google Scholar
• YUSUF S: From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am.j Cardiol (2002) 89:18A–25A.
   Google Scholar
• PITT B, POOL-WILSON PA, SEGAL R et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial — the Losartan Heart Failure Survival Study (ELITE II). Lancet (2000) 355:1582–1587.
   Google Scholar
• PFEFFER MA, MCMURRAY JJV, VELAZQUEZ EJ et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. The Valsartan In Acute Myocardial Infarction (VALIANT) Trial Investigators. N Engl. J. Med. (2003) 349:1893–1906.
   Google Scholar
• ••A large, multi-centre, multinational study,showing similar beneficial effects of valsartan monotherapy, combination therapy with captopril, or monotherapy with captopril in postIVII patients complicated by heart failure, LV systolic dysfunction, or both.
   Google Scholar
• AMERICAN DIABETES ASSOCIATION: Diabetic nephropathy. Diabetes Care (2002) 25 (Suppl. 1):585–589.
   Google Scholar
• CHOBANIAN AV, BAKRIS GL, BLACK HR et a/.: The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. The JNC-7 Report. JAMA (2003) 289:2560–2571.
   Google Scholar
• ••Recent JNC-7 report on evaluation andtreatment of hypertension.
   Google Scholar
• Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA (2002) 288:2981–2997.
   PubMed Web of Science ®Google Scholar
• ••The largest outcome study on theantihypertensive effects and cardiovascular risk reduction of chlorothalidone compared to arnlodipine and lisinopril.
   Google Scholar